Skip to main content
MedinCell demonstrates in vivo the efficacy of the first injectable combining surgical anesthesia and 3 days opioid free postoperative pain management
March 11, 2019
MedinCell receives funding for the second formulation phase of its 6-month injectable contraceptive
January 24, 2019
Publication of the 2019 Financial Calendar
January 15, 2019
Publication of the activity report and financial information for the first half-year (April – Sept. 2018)
December 3, 2018
Publication of the activity report and financial information for the first half-year on December 3, 2018
November 27, 2018
Partial exercise of the over-allotment option – Final amount of the share issue increased to €31.4m
November 5, 2018
Successful IPO of MedinCell
October 3, 2018
Teva to participate in MedinCell Initial Public Offering
September 26, 2018
MedinCell announces the extension of the subscription period for the shares offered as part of its initial public offering
September 25, 2018
MedinCell launches its initial public offering on the regulated market of Euronext in Paris
September 17, 2018
